ClinicalTrials.gg
CompletedNCT06423079Updated May 21, 2024

Scleral Fixation for Intraocular Lens-Bag Dislocation

An observational study in Pseudoexfoliation Syndrome, sponsored by University of Naples. Completed at 1 site in Italy. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2024-05-21.

Sponsored by University of Naples · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
36
Ages
18 Years to 90 Years
Sex
All
01

Study summary

Novel introflective sutures offer a minimally invasive approach for stable fixation of dislocated bag-IOL complexes, preserving visual acuity and reducing corneal complications in patients with pseudoexfoliation syndrome.

Read the detailed description

To assess the one-month outcomes of visual performance and positional stability of capsule-fixated intraocular lenses (IOLs) in patients with IOL-Bag complex dislocation. Patients with intraoperative complications or prior posterior capsule Nd-YAG laser were excluded. Surgical intervention involved creating a superior service keratotomy and using introflective sutures for IOL fixation. Best Corrected Visual acuity (BCVA), endothelial cell counts, and tonometry were assessed at multiple postoperative time points. We also evaluated the mean spherical equivalent (SE), and the residual cylinder and sphere at each follow-up.

02

Conditions studied

  • Pseudoexfoliation Syndrome

Browse trials for

03

In context

Exfoliation Syndrome

72 studies on the registry are indexed under Exfoliation Syndrome; 20 are open to participants now.

This study's enrollment of 36 is below the median of 76 across 38 observational studies indexed under Exfoliation Syndrome.

Browse Exfoliation Syndrome studies →

Lead sponsor

University of Naples is the lead sponsor of 11 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

patients affected by pseudoexfoliation syndrome, with inferior dislocation of the bag-IOL complex after cataract surgery.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients affected by pseudoexfoliation syndrome, with inferior dislocation of the bag-IOL complex

Exclusion criteria

Exclusion Criteria:

  • patients who underwent intraoperative complications,
  • dislocation in the vitreous chamber of the bag-IOL complex,
  • patients who had already undergone posterior capsule Nd-YAG laser
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
36 participants (actual)
Patient registry
No

Groups and cohorts

  • IOL-Bag Dislocation patients

    Patients affected by pseudoexfoliation syndrome, with inferior dislocation of the bag-IOL complex.

    Procedure: Siepser knots

Interventions

  • ProcedureSiepser knots

    Surgical intervention involved creating a superior service keratotomy and using introflective sutures for IOL fixation

06

What researchers measure

Primary outcomes

  1. Best corrected visual acuity

    to evaluate the best corrected visual acuity after the surgery

    Time frame: 1 year

Secondary outcomes

  1. Endothelial cells count

    to evaluate the Endothelial cells count after the surgery

    Time frame: 1 year

07

Study locations

1 site
  • University of Naples Federico II
    NAples, 80131, Italy
08

References and documents

Individual participant data

Plan to share: Yes — all collected IPD

Time frame: 5 years

Access criteria: available on request

Data sharing details ↗ · guides.lib.umich.edu

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2017 to primary completion in May 2019, 24 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2024
First posted
May 21, 2024
StartActual
May 10, 2017
Primary completionActual
May 10, 2019
CompletionActual
May 10, 2022
Last update
May 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06423079
Lead sponsor
University of Naples
Responsible party
Luca D'Andrea (Prinicipal investigator, University of Naples) — Principal investigator
First posted
May 21, 2024
Start date
May 10, 2017
Primary completion
May 10, 2019
Completion
May 10, 2022
Last update
May 21, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion